Core Viewpoint - The company anticipates a revenue of no less than RMB 2.5 billion for the year, representing a growth rate of over 30% compared to the same period last year, along with a net profit of no less than RMB 150 million [1] Group 1: Business Performance - The aesthetic medicine segment is expected to achieve revenue exceeding RMB 1.4 billion and a segment profit of over RMB 700 million, with both revenue and profit growth rates exceeding 90% year-on-year, becoming the largest revenue and profit contributor for the company [1] - The innovative drug business is entering a harvest phase, with combined revenue from XuanZhu Bio and HuiSheng Bio significantly increasing compared to the previous year, and the commercialization of new products progressing smoothly, indicating a transition from investment to profitability for this segment [1] Group 2: Financial Health - The company maintains a robust financial position with ample cash reserves, having implemented multiple rounds of share buybacks and successfully completed the spin-off listing of XuanZhu Bio, which has led to significant equity appreciation and alleviated R&D funding pressures, thereby optimizing the company's financial structure and driving profit breakthroughs [1]
四环医药：预计2025年营收同比超30%至不低于25亿元，医美同比增速超过90%